GlassScriptPhysician profile
Donald Goodin
NPI 1922102391
$16,153.56
in general payments reported to CMS, 2019-2025
76 companies · $3,608 in 2025
The $3,608 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $475 · 2021: $1,406 · 2022: $2,612 · 2023: $2,914 · 2024: $3,636 · 2025: $3,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $47.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,110.02 |
| Education | $47.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,382.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,135.23 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $888.62 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Janssen Biotech, INC. | $881.51 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Daiichi Sankyo INC. | $810.66 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $771.09 | 2019-2025 | Tecentriq, Venclexta, Lunsumio |
| Pfizer INC. | $726.48 | 2019-2025 | |
| Amgen INC. | $586.42 | 2019-2024 | Lumakras, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $573.63 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Eisai INC. | $510.16 | 2020-2025 | |
| Genzyme Corporation | $446.25 | 2019-2025 | |
| Incyte Corporation | $434.39 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $389.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $384.81 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $365.83 | 2021-2025 | Trodelvy |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $340.86 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Seagen INC. | $274.76 | 2019-2023 | Padcev, Adcetris |
| Lilly USA, LLC | $227.71 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $225.84 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Array Biopharma INC | $224.49 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $220.51 | 2019-2025 | Bavencio, Tepmetko |
| Regeneron Healthcare Solutions, INC. | $219.58 | 2022-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $208.61 | 2019-2025 | |
| Coherus Oncology, INC. | $208.56 | 2020-2024 | |
| Aveo Pharmaceuticals, INC. | $202.28 | 2022-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $180.44 | 2020-2025 | Xpovio |
| Sun Pharmaceutical Industries INC. | $174.42 | 2021-2025 | Odomzo, Yonsa |
| Puma Biotechnology, INC. | $171.07 | 2020-2025 | |
| Astellas Pharma US INC | $170.36 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Blueprint Medicines Corporation | $154.71 | 2024-2025 | Ayvakit |
| Stemline Therapeutics INC. | $146.35 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $135.78 | 2019-2023 | Ultomiris |
| Beigene USA, INC. | $135.28 | 2021-2024 | Brukinsa |
| Tersera Therapeutics LLC | $126.18 | 2019-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $114.73 | 2021-2025 | Onivyde, Somatuline Depot |
| Adc Therapeutics America, INC. | $111.92 | 2022-2024 | |
| Geron Corporation | $108.12 | 2025 | Rytelo |
| Taiho Oncology, INC. | $107.51 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.46 | 2019-2025 | Gilotrif |
| Tempus Ai, INC | $104.12 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $102.98 | 2019-2023 | Imbruvica |
| Kite Pharma, INC. | $101.45 | 2021-2025 | Yescarta |
| Sobi, INC | $96.14 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $82.10 | 2023-2024 | Rezlidhia, Tavalisse |
| Pharmacosmos Therapeutics INC. | $72.83 | 2021-2024 | Monoferric, Cosela |
| Genmab U.S., INC. | $71.19 | 2024-2025 | Tivdak |
| Jazz Pharmaceuticals INC. | $69.65 | 2019-2025 | |
| Mirati Therapeutics, INC. | $65.95 | 2023-2024 | Krazati |
| Exelixis INC. | $56.84 | 2023-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $55.14 | 2022-2025 | Besremi |
| Morphosys, US INC. | $53.36 | 2022-2023 | Monjuvi |
| G1 Therapeutics, INC. | $49.94 | 2022-2023 | Cosela |
| Sumitomo Pharma America, INC. | $48.41 | 2023-2024 | Orgovyx |
| Fennec Pharmaceuticals, INC. | $43.66 | 2023-2024 | Pedmark |
| Springworks Therapeutics, INC. | $38.57 | 2024-2025 | Gomekli, Ogsiveo |
| Clovis Oncology, INC. | $32.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $32.60 | 2019-2020 | |
| Kyowa Kirin, INC. | $31.80 | 2020-2023 | Poteligeo |
| Dova Pharmaceuticals | $30.01 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.80 | 2025 | Givlaari |
| Myovant Sciences INC. | $27.23 | 2022 | |
| Progenics Pharmaceuticals, INC. | $24.37 | 2024 | |
| Tg Therapeutics, INC. | $23.69 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $22.76 | 2024 | Sancuso |
| Accord Healthcare, INC. | $22.71 | 2025 | |
| Recordati_rare_diseases_inc. | $21.39 | 2025 | Enjaymo |
| Verity Pharmaceuticals INC. | $19.57 | 2023 | Trelstar |
| Apellis Pharmaceuticals, INC. | $18.21 | 2023 | Empaveli |
| Caris Mpi, INC. | $17.58 | 2025 | Mi Cancer Seek |
| Novocure INC. | $17.31 | 2021 | |
| Cti Biopharma Corp. | $16.96 | 2023 | Vonjo |
| Medtronic, INC. | $15.58 | 2023 | Synchromedii |
| Foundation Medicine, INC. | $15.36 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.90 | 2025 | Danziten, Vivimusta |
| Organon LLC | $13.66 | 2022 | |
| Tesaro, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
Keytruda $633Enhertu $462Venclexta $294Lenvima $275Darzalex $272Kisqali $266Tagrisso $245Fruzaqla $230Xtandi $222Tukysa $220Tecvayli $205Imbruvica $203Reblozyl $202Opdivo $200Lynparza $199Jakafi $193Pluvicto $191Orgovyx $187Ibrance $178Fotivda $175Epkinly $161Braftovi $160Mektovi $160Ayvakit $155Rybrevant $151Padcev $149Scemblix $148Trodelvy $146Orserdu $146Lorbrena $141Talzenna $140Tecentriq $138Datroway $134Erleada $134Udenyca $128Ninlaro $127Libtayo $122Monjuvi $117Jaypirca $114Verzenio $114Welireg $112Nubeqa $111Odomzo $111Yonsa $111Rytelo $108Fabhalta $108Piqray $99.28Sarclisa $95.91Enjaymo $88.50Zejula $86.64Jemperli $86.64Iclusig $85.58Xpovio $85.51Zoladex $82.99Tavalisse $82.10Rezlidhia $82.10Zynyz $75.98Ojjaara $75.87Lutathera $75.85Tivdak $71.19Lonsurf $68.68Inqovi $68.68Nerlynx $67.93Lunsumio $66.57Krazati $65.95Adcetris $62.62Brukinsa $61.24Talvey $60.77Inlyta $59.07Pemazyre $57.37Cabometyx $56.84Onivyde $55.38Ultomiris $53.11Doptelet $52.65Elrexfio $50.49Stivarga $50.37Vitrakvi $50.37Promacta $49.92Bavencio $49.60Carvykti $48.37Alunbrig $47.97Xofigo $47.45Vonjo $45.98Yescarta $45.64Pedmark $43.66Polivy $41.79Monoferric $41.40Besremi $40.92Retevmo $36.72Bosulif $35.67Xalkori $35.48Lynozyfic $34.78Besponsa $34.53Phesgo $33.03Injectafer $32.70Givlaari $29.80Gilotrif $29.38Cosela $28.51Mekinist $24.90Pylarify $24.37
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Goodin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.